Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SNGX seems legit with "$7.1m cash on 3/31/2024"? But PPS ???
"Dr. Schaber continued, "With approximately $7.1 million in cash at March 31, 2024, exclusive of the approximate $4.3 million in net proceeds from our recent financing and our non-dilutive government funding, we continue to manage cash burn very carefully to achieve our near-term milestones. We have a clear vision for the future, and we are actively pursuing new opportunities to create long-term value for our shareholders including but not limited to, partnership and merger and acquisition opportunities."
Soligenix Recent Accomplishments
1) On April 25, 2024, the Company announced it had received notice of intent to grant additional patents based on its patent application titled "Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines" in the United Kingdom and South Africa, with other international jurisdictions pending. To view this press release, please click here.
2) On April 18, 2024, the Company announced the pricing of its public offering of 11,875,000 shares of common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrants for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. To view this press release, please click here.
3) On April 15, 2024, the Company announced the Office of Orphan Products Development of the U.S. FDA had granted orphan drug designation to the active ingredient in SuVax™, the subunit protein vaccine of recombinantly expressed SUDV glycoprotein, for "the prevention and post-exposure prophylaxis against SUDV infection." To view this press release, please click here.
4) On April 11, 2024, the Company announced the Office of Orphan Products Development of the U.S. FDA had granted orphan drug designation to the active ingredient in MarVax™, the subunit protein vaccine of recombinantly expressed MARV glycoprotein, for "the prevention and post-exposure prophylaxis against MARV infection." To view this press release, please click here.
5) On April 3, 2024, the Company announced it had received agreement from the EMA on the key design components of a confirmatory Phase 3 placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synthetic hypericin) in the treatment of CTCL patients with early-stage disease. To view this press release, please click here.
Financial Results – Quarter Ended March 31, 2024
- Soligenix's revenues for the quarter ended March 31, 2024 were $0.1 million as compared to $0.3 million for the quarter ended March 31, 2023. Revenues primarily relate to government contracts and grants awarded in support of SGX943 for treatment of emerging and/or antibiotic-resistant infectious diseases; development of CiVax™, our vaccine candidate for the prevention of COVID-19, and evaluation of HyBryte™ for expanded treatment in patients with early-stage CTCL.
- Soligenix's net loss was $1.9 million, or ($0.18) per share, for the quarter ended March 31, 2024, as compared to $1.0 million, or ($0.36) per share, for the quarter ended March 31, 2023. The increase in net loss was primarily due to the recognition of an income tax benefit during the three months ended March 31, 2023 with no corresponding income tax benefit recognized during the three months ended March 31, 2024.
- Research and development expenses were $1.1 million as compared to $0.9 million for the quarters ended March 31, 2024 and 2023, respectively. The increase was primarily due to an increase in preliminary costs associated with the anticipated initiation of our Phase 2 study in Behçet's Disease and the second confirmatory Phase 3 CTCL trial.
- General and administrative expenses were $1.0 million and $1.2 million for the quarters ended March 31, 2024 and 2023, respectively. This decrease in general and administrative expenses is primarily attributable to a reduction in legal and professional fees associated with the reverse stock split of our issued and outstanding shares of common stock during the three months ended March 31, 2023.
- As of March 31, 2024, the Company's cash position, exclusive of the approximate $4.3 million in net proceeds from our recent financing, was approximately $7.1 million."
GLTA
...
..
.
SNGX sure showing breakdown !
Does SNGX 5/22 meeting doc show potential r/s? Again?
SNGX already did 1 reverse split but Schaber doesn’t care about PPS so allows to tank, dilute, reverse, repeat…
Good business. For him
Schaber such a skank dilute with .40 shares with supposed millions in cash on hand???
Definitely orchestrated pump with DUMP hard so far today…
Schaber only looking to keep his salary afloat by adding shares??
GLTA
Thanks. SNGX horribly short pop…
And down SNGX goes..
Too many prior “orphan grants” and nothing happens…
GLTA
JNUG been there before!
GLTA
Lookin good JNUG !
I even averaged down a bit
Wish I had more $$$ for DJT dip…
Down on 2m traded vs 20m daily average….
Hmmmmmm
Abstaraeniatet…
(Only swear I remember from Russia class)
Trump will prevail.
DJT will create wealth…
GLTA
That’s a poker face for sure.
This will likely exceed $50+ within the next 5 trading days…
And we can say 54, 64, 74, and 84 !!!
My shares are GTC at $110.50 !
GLTA
WTH with Bitcoin up $3k today
MARA looking like mud with Bitcoin up $3k
Agreed. I'm back in RIOT...
GLTA
Nice try Dr Shabby with repeat PR: "April 3, 2024 Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study"...
BS press release after yesterday 4/2 filing for your 16m share dilution AGAIN...
How LOW do you take SNGX ???
Schaber must need few bucks so planning another RS.
Nice business.
Jim Cramer should go down with this ship show as he promoted it….
Trump 2024 ! DJT on the way UP…
And by the way - everyone here in the USA will tell you - EVERY Frenchman is WRONG !!!
GLTA
There you have it...
Mainipulation here at DJT likely be same as reddit, and pop hard 2-3 days later...IMO?
GLTA
Agreed. This is just the everyday lull 11am-1pm EST....
After 3pm EST going to be interesting right in to after-hours...
GLTA
DJT $79s !!!
GLTA
Easy ignore as board seats to keep down the noise & see what DJT has for us.
GLTA
DJT $64+ pre-market !
All my shares show!
GLTA
Can’t find DJT pre-market prices yet.
GLTA
Libel must be documented. Message boards do not count.
Now the wiser
I have all docs and zero on r/s .
Slander is illegal
Why the DWAC drop this morning?
Doesn’t make sense?
GLTA
Why'd this USAS board die?
Seems this week is good opportunity with USAS with gold minor dip before the run UP...
GLTA
Thanks I forgot.
I’ll add
Why the DWAC drop today?
Wow IMPP ! For the 12 months ended December 31, 2023, revenues were $183.7 million, up 89.4% from the previous year, while net income increased by 141% to $71.1 million. The company held $124 million in cash and equivalents as of December 31, 2023.
GLTA !
Appreciated CC ! I'm almost at my average after 18mo...
GLTA
CALC another $35 and back to even!
My 1st DWAC buy was $62…
Let’s go DWAC !
You said that 20% ago.
NH win boosts DWAC higher …